Another medical device company has gone public on the Hong Kong Stock Exchange. What is the "gold content" of MicroTech (02041)?

As multiple medical device companies reveal their interim reports, the overall recovery trend in the medical device sector is clear, with an upward inflection point emerging in performance results. According to statistics, in the first half of 2026, the CSI All China Medical Devices Index reported a year-on-year revenue growth of 7.62% and a net profit increase of 10.49%, marking the first quarter in four years to achieve positive net profit attributable to shareholders. On September 7, 2023, Maiketan (02041) was officially listed on the Hong Kong Stock Exchange, which means that the Hong Kong stock markets medical device sector has gained another leading platform company. As the medical device sector shows signs of recovery, what key aspects of Maiketan's listing should investors pay attention to, and what will be the future development trends in the industry? The following analysis will provide detailed insights. The Medical Device Industry Shows Signs of Rebound, with Commercialization Ability Becoming a Market Focus Against the backdrop of a rapidly aging global population, continuous innovations in cutting-edge medical technologies, and an ever-increasing demand for health, the medical device industry has maintained a steady growth trend over the long term. According to several authoritative institutions, the global medical device market size is expected to reach between $600 billion and $800 billion in 2026, with a forecast to exceed $1 trillion by 2035. In the first half of 2026, there were 814 financing events in China's healthcare sector, a year-on-year increase of 13.8%. The total financing amounted to 72.56 billion yuan, a year-on-year growth of 41.7%, clearly demonstrating a "volume and price increase" trend, indicating a significant rise in capital market interest. In terms of capital flows, innovation drugs, medical devices, and IVD fields remain the main areas for investment, with large financing increasingly focusing on projects that demonstrate clinical progression, product validation, or industrialization capabilities. At a time when the capital market increasingly seeks certainty, a company's commercialization ability and profitability are gradually becoming "hard indicators" for evaluating its true value. Taking Maiketan as an example, the company is at a pivotal point of transitioning from losses to profitability. From 2023 to 2025, the company's total revenue is projected to grow from 1.313 billion yuan to 1.619 billion yuan, with a compound annual growth rate of about 11%. The gross profit margin is expected to increase from 49.6% to 53.7%, showing a clear upward trend. Although there were initial losses due to the amortization of merger and acquisition costs and other factors, losses have narrowed year by year, with a return to profitability expected in 2025. Entering 2026, the company's performance improvement momentum is further accelerating. In the first three months, revenue grew year-on-year by 19.1% to 422 million yuan, with adjusted profits reaching 35 million yuan, a significant increase of 132% compared to 15.1 million yuan during the same period last year. It is worth noting that in the first half of 2026, the company incurred a share-based payment expense of 25.065 million yuan; excluding the impact of such non-cash/non-operating factors, the companys core business is already in a profitable state. In terms of cash flow, in the first three months of 2026, cash flows from operating activities turned positive, with cash and cash equivalents at the end of the period amounting to 321 million yuan, indicating that the company has established self-sustaining capabilities. The growth logic of the medical device industry is essentially a process of "accumulating talent before bursting forth," where companies need to steadily build product and technological barriers through long-term, large-scale R&D investments. Today, the emergence of a profitability inflection point is undoubtedly a positive signal, indicating that Maiketan has moved past the "burning cash" investment period. Leverage the strong defenses built through the companys technology, products, and channels to enter a new phase of sustainable operations. Industry Competition Logic Shift, Platform Companies Expected to Benefit First Currently, the global medical device industry is accelerating towards high-end and platformization. Under this trend, single product lines struggle to build lasting competitive barriers. In the long run, companies with complete product matrices and ongoing expansion of ecological layouts are more likely to gain larger market shares in fierce competition. As industry competition intensifies, medical device companies are increasingly focused on resource integration through mergers and acquisitions to expand scale, enhance market concentration, and improve overall competitiveness. Leading enterprises frequently utilize external mergers to enrich their product lines and technology reserves, further solidifying their competitive advantages. Focusing on the enterprise level, Maiketan has chosen the typical "platformization" path in the medical device industry, aiming to create a platform business system that spans multiple fields and regions. Maiketan started with drug infusion products and has now extended across the three major areas of life support, minimally invasive intervention, and in vitro diagnosis, with a product portfolio that includes over 60 life support products, 110 minimally invasive intervention products, and 150 in vitro diagnostic products. Although these three business segments belong to different tracks, they can create reuse and synergies in terms of channels, customers, and technology, widely covering clinical needs in clinical departments, wards, clinics, community health centers, testing institutions, and home care settings. According to ZhiShi Consulting's data, with innovative and high-quality medical products, as well as extensive coverage in clinical departments, the company has become one of the most comprehensive medical device companies in China. This diversification strategy not only allows the company to effectively resist the risk of volatility from a single track and enhance performance security but also facilitates the creation of new growth curves, enabling overall robust development. In terms of performance, all three major business segments of Maiketan have achieved comprehensive growth in the past three years, validating the feasibility of this strategy. Among them, the life support segment maintained revenue of 500-600 million yuan from 2023 to 2025, with a gross profit margin of 44.9% in the first three months of 2026. The minimally invasive intervention segment saw its revenue soar from 587 million yuan to 812 million yuan over three years, with the gross profit margin increasing from 55.3% in 2023 to 61.8% in the first three months of 2026, becoming the core engine driving the companys overall growth. The in vitro diagnostic business has continued to grow, recording nearly 200 million yuan in revenue in 2025, maintaining a high gross profit margin of 53.3% in the first three months of 2026. Having a broadly laid product matrix is one aspect, but on the other hand, the technical strength of each of Maiketans products is also top-notch. In the life support segment, the company launched the worlds first remote infusion control system and the first domestically developed multi-channel infusion workstation, an infusion workstation compatible with MRI environments, touch-sensitive infusion pumps, and touch-sensitive enteral nutrition pumps. According to sales revenue, from 2018 to 2025, it has held the top position in Chinas infusion workstation market for eight consecutive years, and from 2021 to 2025, it ranked first for five consecutive years in the enteral nutrition pump market. In the minimally invasive intervention segment, the company is one of the few domestic brands in China with proprietary endoscopic product portfolios. Based on sales revenue, it ranked among the top three in Chinas minimally invasive interventional consumables market for four consecutive years from 2022 to 2025 and has entered the top five in China's disposable choledochoscope market for three consecutive years from 2023 to 2025. In the in vitro diagnostic segment, the company launched the worlds first fully automated thromboelastography analyzer in 2021, entering the top five in the Chinese blood type testing equipment market based on sales revenue by 2025. Leading technology and market share not only indicate that the company possesses robust technical barriers but also that it is mature enough in commercialization, which further confirms the substantial value of its performance growth. High-end Medical Devices Accelerate "Going Global," Overseas Markets Contribute New Growth Currently, going global has become one of the most important growth directions for domestic medical device companies. According to statistics from China Meheco Groups Health Products Import and Export Chamber of Commerce, in the first half of 2026, China's total medical device exports reached $27.1 billion, a year-on-year increase of 12.4%, while imports amounted to $15.46 billion, a year-on-year decline of 9%, resulting in a trade surplus of $11.64 billion in the first half of the year. High-end medical devices continue to achieve breakthroughs in mature markets such as Europe and the United States, while benefiting from the upgrade of medical demand in emerging markets and the deepening collaboration within the "Belt and Road" participating countries. The market penetration of domestic medical devices in regions such as ASEAN, Latin America, and Central Asia has also steadily increased. Maiketan began its dual deployment in both domestic and international markets early on, and overseas operations have become a standout feature of the companys fundamentals. Domestically, Maiketan's products have reached over 6,000 hospitals, including approximately 90% of Class III hospitals and covering all 31 provinces, municipalities, and autonomous regions. By the end of 2025, the company had obtained over 300 medical device registration certificates from national medical device authorities and more than 40 FDA certifications, along with over 300 CE-certified products. Internationally, the company has established a footprint across the Asia-Pacific, Europe, the Middle East, Africa, and the Americas, covering more than 140 countries and regions, with over 3,707 global distributors. By 2025, overseas revenue accounted for 48.3% of the total, becoming a crucial revenue pillar. Through the acquisition of the UK medical device company Penlon and the European medical device distributor Vedefar, the company has consolidated its presence in the European market, with revenue from Europe, the Middle East, and Africa (EMEA) accounting for 26.6% by 2025. According to the IPO plan, approximately 35% of the net proceeds from Maiketans listing will be allocated to R&D investments, 20% to the expansion of manufacturing bases, 20% to enhancing sales and marketing capabilities, and 10% to potential acquisition opportunities. This funding allocation clearly indicates the company's growth strategy moving forward: ongoing investment in R&D to ensure product innovation and iteration, increased production capacity to support rapid commercialization, continued deepening of global layouts, while maintaining sensitivity to quality acquisition targets. By making multi-faceted efforts, the company aims to continue scaling up and deepening its competitive advantages based on its existing platform. Overall, with Maiketans recent listing on the Hong Kong stock exchange, the profitability inflection point has been confirmed, the commercialization path is mature, and the comprehensive product portfolio and global layout of the platform company have provided sufficient safety margins, making it a quality target in the medical device sector with ample certainty. In light of this IPO window, market investors might consider potential long-term investment opportunities.